MONTREAL, CANADA AND LILLE, FRANCE -- (MARKET WIRE) -- September 26, 2006 -- Pathogen Removal and Diagnostic Technologies Inc. (“PRDT”), a joint venture between ProMetic Life Sciences Inc. (TSX: PLI) and the American Red Cross, along with PRDT’s commercial and manufacturing partner, MacoPharma SA (“MacoPharma”), announced at the British Blood Transfusion Society Meeting, Bournemouth, 21-23rd September, 2006, that their prion capture filter, P-Capt™, targeted initially at reduction of TSE pathogens from red blood cell concentrate, has received European Regulatory Approval (CE mark).
